Quest Diagnostics (DGX) PT Raised to $226 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Nasdaq futures gain as SK Hynix lifts chips ahead of Fed decision, earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil up over 1% as Saudi Arabian refinery attack reignites supply risk concerns
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
Tweet
Share
E-mailGet Alerts DGX Hot Sheet
Price: $242.56 --0%
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 12 | New: 16
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 12 | New: 16
Join SI Premium – FREE
Morgan Stanley analyst Erin Wright raised the price target on Quest Diagnostics (NYSE: DGX) to $226.00 (from $207.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Marzetti Company (MZTI) PT Lowered to $135 at Stephens
- CommVault Systems (CVLT) PT Raised to $200 at Guggenheim
- TransUnion (TRU) PT Raised to $95 at Needham
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
